v3.26.1
Segment Information - Schedule of Significant Expense Categories Provided to CODM (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting [Line Items]        
Revenues $ 287 $ 316 $ 685 $ 697
Less:        
Cost of revenues 105 170 239 276
R&D costs 3,194 2,954 5,513 5,469
G&A costs 3,159 2,589 5,879 5,530
Net loss (6,073) (5,028) (10,809) (10,039)
Reportable Segment [Member]        
Segment Reporting [Line Items]        
Revenues [1] 287 316 685 697
Less:        
Cost of revenues 105 170 239 276
R&D costs [2] 952 739 1,524 1,225
G&A costs [3] 1,904 1,387 3,589 2,788
Personnel costs [4] 3,065 2,961 5,503 5,983
Other segment items [5] 334 87 639 464
Net loss $ (6,073) $ (5,028) $ (10,809) $ (10,039)
[1] Includes Contract Manufacturing and Clinical Trial revenue
[2] Includes Clinical Development, Research & Discovery, CMC
[3] Includes Executive, Finance, Legal, Business Operations
[4] Includes compensation, benefits and equity-based compensation
[5] Includes depreciation and amortization, (interest income) and other specific charges